CORRECTING and REPLACING Kopin Reports Results for Third Quarter 2022
-
Total Revenues increase
8% year-over-year -
Defense Revenues Increase
68% year-over-year
The Company revised its Accounting Standards Codification Topic 606 (ASC 606) over time revenue recognition related to defense contracts which resulted in a decrease of approximately
The revised revenue results is as follows:
-
Total revenues for the three and nine months ended
September 24, 2022 were and$11,729,380 , respectively. These represent an$35,216,834 8% year over year increase for the three months endedSeptember 24, 2022 . -
Revenues from the sale of defense products were
and$5,851,425 for the three and nine months ended$17,695,160 September 24, 2022 , respectively. This represents a68% year over year increase for the three months endedSeptember 24, 2022 . -
Net Loss Attributable to
Kopin Corporation for the third quarter of 2022 was , or$6.1 million per share, compared with Net Loss Attributable to$0.07 Kopin Corporation of , or$2.1 million per share, for the third quarter of 2021.$0.02
The updated release reads:
KOPIN REPORTS RESULTS FOR THIRD QUARTER 2022
-
Total Revenues increase
8% year-over-year -
Defense Revenues Increase
68% year-over-year
“We had a good quarter with revenues up
Murray continued, “As we move into 2023 I see numerous opportunities to drive revenues, beginning with accelerating growth from our defense and industrial businesses, where we already have a solid order book. We will also leverage our unique ability to offer complex integrated optical display assemblies, which are critical to increasing the applications for AR/VR/MR, among other opportunities.”
“Technology has always been at the heart of Kopin’s success and we will continue executing on our vision to provide our global customers with brilliance in innovation, design and performance paired with a renewed focus on operational excellence,” concluded Murray.
Third Quarter Financial Results
Total revenues for the third quarter ended
Cost of Product Revenues for the third quarter of 2022 was
Research and Development (R&D) expenses for the third quarter of 2022 were
Selling, General and Administration (SG&A) expenses were
Other income and expense included a non-cash impairment charge of
Net Loss Attributable to
In
About Kopin
Kopin is a trademark of
Forward-Looking Statements
Statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the safe harbor created by such sections. Words such as “expects,” “believes,” “can,” “will,” “estimates,” and variations of such words and similar expressions, and the negatives thereof, are intended to identify such forward-looking statements. We caution readers not to place undue reliance on any such “forward-looking statements,” which speak only as of the date made, and advise readers that these forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by us that are difficult to predict. These forward-looking statements include statements with respect to our numerous opportunities to drive revenues in 2023; such as accelerating growth from our defense and industrial businesses; our growth in the defense and consumer markets; and our intent to leverage our unique ability to offer complex integrated optical display assemblies. Various factors, some of which are beyond our control, could cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. All such forward-looking statements, whether written or oral, and whether made by us or on our behalf, are expressly qualified by these cautionary statements and any other cautionary statements that may accompany the forward-looking statements. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as may otherwise be required by the federal securities laws. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations are described in Part I, Item 1A. Risk Factors; Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and other parts of our Annual Report on Form 10-K for the fiscal year ended
|
||||||||||||
Supplemental Information |
||||||||||||
(Unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
|
|
|
|
|
|
|
||||
Display Revenues by Category (in millions) | ||||||||||||
Defense | $ |
5.8 |
$ |
3.5 |
$ |
17.7 |
$ |
12.3 |
||||
Industrial/Enterprise |
|
1.7 |
|
2.7 |
|
4.9 |
|
7.4 |
||||
Consumer |
|
0.7 |
|
0.4 |
|
1.2 |
|
1.3 |
||||
R&D |
|
3.4 |
|
4.1 |
|
11.1 |
|
10.4 |
||||
License and Royalties |
|
0.1 |
|
0.2 |
|
0.3 |
|
1.1 |
||||
Total | $ |
11.7 |
$ |
10.9 |
$ |
35.2 |
$ |
32.5 |
||||
Stock-Based Compensation Expense | ||||||||||||
Cost of product revenues | $ |
42,000 |
$ |
38,000 |
$ |
120,000 |
$ |
207,000 |
||||
Research and development | $ |
112,000 |
|
180,000 |
|
368,000 |
|
395,000 |
||||
Selling, general and administrative | $ |
144,000 |
|
424,000 |
|
883,000 |
|
3,165,000 |
||||
$ |
298,000 |
$ |
642,000 |
$ |
1,371,000 |
$ |
3,767,000 |
|||||
Other Financial Information | ||||||||||||
Depreciation and amortization | $ |
130,000 |
$ |
154,000 |
$ |
665,000 |
$ |
566,000 |
||||
Condensed Consolidated Statements of Operations |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
Revenues: | ||||||||||||||||
Net product revenues | $ |
8,254,686 |
|
$ |
6,591,852 |
|
$ |
23,765,872 |
|
$ |
21,089,515 |
|
||||
Research and development and other revenues |
|
3,474,693 |
|
|
4,295,321 |
|
|
11,450,961 |
|
|
11,379,282 |
|
||||
|
11,729,379 |
|
|
10,887,173 |
|
|
35,216,833 |
|
|
32,468,797 |
|
|||||
Expenses: | ||||||||||||||||
Cost of product revenues |
|
7,987,154 |
|
|
5,145,175 |
|
|
23,676,283 |
|
|
17,586,389 |
|
||||
Research and development |
|
3,441,405 |
|
|
3,751,729 |
|
|
13,995,393 |
|
|
11,055,282 |
|
||||
Selling, general and administration |
|
4,320,117 |
|
|
4,035,998 |
|
|
13,112,133 |
|
|
13,982,682 |
|
||||
|
15,748,676 |
|
|
12,932,902 |
|
|
50,783,809 |
|
|
42,624,353 |
|
|||||
Loss from operations |
|
(4,019,297 |
) |
|
(2,045,729 |
) |
|
(15,566,976 |
) |
|
(10,155,556 |
) |
||||
Other (expense) income, net |
|
(2,093,877 |
) |
|
(50,954 |
) |
|
2,505,949 |
|
|
89,267 |
|
||||
Loss before provision for income taxes and net (income) loss from noncontrolling interest |
|
(6,113,174 |
) |
|
(2,096,683 |
) |
|
(13,061,027 |
) |
|
(10,066,289 |
) |
||||
Tax provision |
|
(36,000 |
) |
|
(32,000 |
) |
|
(108,000 |
) |
|
(97,000 |
) |
||||
Net loss |
|
(6,149,174 |
) |
|
(2,128,683 |
) |
|
(13,169,027 |
) |
|
(10,163,289 |
) |
||||
Net (income) loss attributable to noncontrolling interest |
|
- |
|
|
(107 |
) |
|
280 |
|
|
39,394 |
|
||||
Net loss attributable to |
$ |
(6,149,174 |
) |
$ |
(2,128,790 |
) |
$ |
(13,168,747 |
) |
$ |
(10,123,895 |
) |
||||
Net loss per share: | ||||||||||||||||
Basic and diluted | $ |
(0.07 |
) |
$ |
(0.02 |
) |
$ |
(0.14 |
) |
$ |
(0.11 |
) |
||||
Weighted average number of common shares outstanding: | ||||||||||||||||
Basic and diluted |
|
93,516,231 |
|
|
90,517,330 |
|
|
91,317,288 |
|
|
88,903,658 |
|
||||
Condensed Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and marketable securities | $ |
15,003,009 |
|
$ |
29,295,466 |
|
||
Accounts receivable, net |
|
8,531,835 |
|
|
12,113,070 |
|
||
Inventory |
|
6,660,810 |
|
|
6,581,139 |
|
||
Contract assets and unbilled receivables |
|
4,605,889 |
|
|
2,299,392 |
|
||
Prepaid and other current assets |
|
1,726,225 |
|
|
1,918,678 |
|
||
Total current assets |
|
36,527,768 |
|
|
52,207,745 |
|
||
Plant and equipment, net |
|
1,627,468 |
|
|
1,888,963 |
|
||
Operating lease right-of-use assets |
|
3,540,073 |
|
|
3,828,066 |
|
||
Other assets |
|
170,932 |
|
|
170,932 |
|
||
Equity investments |
|
7,612,065 |
|
|
4,912,022 |
|
||
Total assets | $ |
49,478,306 |
|
$ |
63,007,728 |
|
||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ |
4,936,931 |
|
$ |
5,483,970 |
|
||
Accrued expenses |
|
7,521,147 |
|
|
4,133,379 |
|
||
Contract liabilities and billings in excess of revenue earned |
|
1,097,919 |
|
|
4,063,031 |
|
||
Operating lease liabilities |
|
761,734 |
|
|
701,204 |
|
||
Customer deposits |
|
378,201 |
|
|
2,638,103 |
|
||
Deferred tax liabilities |
|
424,433 |
|
|
513,417 |
|
||
Total current liabilities |
|
15,120,365 |
|
|
17,533,104 |
|
||
Other long term liabilities |
|
1,395,603 |
|
|
2,739,531 |
|
||
Operating lease liabilities, net of current portion |
|
2,753,885 |
|
|
3,108,236 |
|
||
|
30,381,067 |
|
|
39,799,191 |
|
|||
Noncontrolling interest |
|
(172,614 |
) |
|
(172,334 |
) |
||
Total stockholders' equity |
|
30,208,453 |
|
|
39,626,857 |
|
||
Total liabilities and stockholders' equity | $ |
49,478,306 |
|
$ |
63,007,728 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005503/en/
Investor Contacts:
Kopin
Treasurer and Chief Financial Officer
Richard_Sneider@kopin.com
Or
JHorne@marketstreetpartners.com
Source: